SP HMG 75IU

Indication

Human Menopausal Gonadotropin (HMG) 75 IU is a gonadotropic preparation containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity. It is indicated in clinical and research settings requiring direct stimulation of gonadal function, particularly in fertility preservation and endocrine recovery protocols.

In males, HMG is indicated for the stimulation of spermatogenesis and endogenous testosterone production, especially in cases of secondary hypogonadism or suppression of the hypothalamic–pituitary–gonadal (HPG) axis. In females, it is used to support follicular development in assisted reproductive contexts.

HMG plays a critical role in protocols aiming to restore or maintain gonadal responsiveness when endogenous gonadotropin signaling is insufficient.

Contra-Indications

HMG is contraindicated in individuals with:

• Primary gonadal failure where gonadal tissue is non-responsive
• Hormone-dependent malignancies
• Ovarian cysts unrelated to polycystic ovarian syndrome
• Hypersensitivity to gonadotropins

Use during pregnancy is contraindicated unless specifically medically indicated. Uncontrolled thyroid or adrenal dysfunction should be corrected before initiating therapy.

Administration

SP HMG 75 IU is administered via subcutaneous or intramuscular injection, depending on protocol design and clinical preference. Dosing frequency and duration vary widely based on therapeutic objective, sex, and endocrine response.

In males, HMG is often administered several times per week to maintain consistent gonadotropic stimulation. In females, administration is carefully timed and monitored to avoid ovarian hyperstimulation.

Strict adherence to dosing schedules and sterile administration practices is essential.

Medical Action

HMG exerts its effects by supplying exogenous FSH and LH activity, directly stimulating the gonads. In males, LH activity activates Leydig cells, promoting testosterone synthesis, while FSH activity stimulates Sertoli cells, supporting spermatogenesis.

In females, FSH drives follicular growth, while LH supports ovulation and corpus luteum formation. Unlike single-hormone therapies, HMG provides balanced gonadotropic signaling that closely resembles physiological endocrine stimulation.

This dual action makes HMG particularly effective in restoring fertility and gonadal function where isolated stimulation is insufficient.

Precautions

Hormonal monitoring is essential throughout use. Dose adjustments should be guided by laboratory markers and clinical response.

In females, careful ultrasound monitoring is required to prevent ovarian hyperstimulation syndrome (OHSS). In males, monitoring of estradiol and testosterone levels helps maintain hormonal balance.

Side Effects

Potential side effects include:

• Injection-site discomfort
• Hormonal fluctuations
• Mood changes
• Gynecomastia (in males, secondary to estrogen conversion)
• Fluid retention

Serious adverse effects are uncommon when therapy is properly managed.

Conclusion

SP HMG 75 IU is a clinically established gonadotropin preparation with critical applications in fertility and endocrine restoration protocols. By providing both FSH and LH activity, it offers precise and effective gonadal stimulation where endogenous signaling is insufficient.

When used under appropriate supervision, HMG remains a cornerstone agent in reproductive and endocrine medicine.